FOLH1 and prostate cancer: They include a phase 1 trial using the thorium labeled PSMA-TTC (BAY 2315497) immunoconjugate consisting of a human anti-PSMA antibody covalently linked to the chelator moiety (3,2 HOPO) radiolabeled to 227Th for use in patients with metastatic castration resistant prostate cancer [80]; a phase 1 trial using the 227Th-labeled antibody–chelator conjugate MSLN-TTC (BAY 2287411) in patients with mesothelin expressing tumors; and a phase 1 study using the 227Th-labeled antibody BAY2701439 in patients with breast, gastric, gastroesophageal, and other cancers expressing HER2.